(Q43739514)

English

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

scientific article

In more languages
default for all languages
No label defined

No description defined

Statements

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial (English)
A Llombert-Cussac
E Quebe-Fehling

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit